Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11853819 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30625385 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL9308524 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL3361183 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL29442915 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL10448989 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL17157280 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30052812 | 0.98 | KMT2A (0.64) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30288025 | 0.98 | KMT2A (0.64) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL29578686 | 0.97 | LTA4H (0.65) | KMT2AKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| CN-118878633-A | Application of multi-target peptide in preparing analgesic drug | 南通大学 | 2024-11-01 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| US-11692003-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-07-04 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-114835773-A | ACE inhibitory peptide and application thereof | 浙江海洋大学 | 2022-08-02 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3962928-A1 | METHOD FOR TREATING OPIOID USE DISORDER | The Administrators of The Tulane Educational Fund (US) | 2022-03-09 | — | — | EP | claimed |
| US-20220056075-A1 | METHOD FOR TREATING OPIOID USE DISORDER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-02-24 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| CN-121633234-A | Innovative dual-mode detection method based on dipeptide nano-framework and high-efficiency application of detection method in helicobacter pylori | 宁波大学 | 2026-03-10 | — | — | CN | disclosed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3962928-A1 | METHOD FOR TREATING OPIOID USE DISORDER | The Administrators of The Tulane Educational Fund (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962922-A1 | METHOD FOR PRODUCING PEPTIDES OR PROTEINS OR PEPTIDOMIMETICS | Strainchem (FR) | 2022-03-09 | — | — | EP | disclosed |
| US-20220056075-A1 | METHOD FOR TREATING OPIOID USE DISORDER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220033429-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNITED STATES GOVERNMENT | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | KMT2A 2979/4885KDM4E 3188/4885MEN1 2308/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | KMT2A 1801/4885KDM4E 1136/4885MEN1 1217/4885 |
| US-11692003-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | MELK, TFAM, MDK | KMT2A 183/4885KDM4E 362/4885MEN1 797/4885 |
| US-20220033429-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | MELK, TFAM, MDK | KMT2A 183/4885KDM4E 362/4885MEN1 797/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | KMT2A 1142/4885KDM4E 984/4885MEN1 3411/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | KMT2A 3254/4885KDM4E 3149/4885MEN1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.